Pharmacotherapy Original research| Volume 34, ISSUE 8, P1761-1771, August 2012

Combination Treatment With Ipragliflozin and Metformin: A Randomized, Double-Blind, Placebo-Controlled Study in Patients With Type 2 Diabetes Mellitus



      Ipragliflozin (ASP1941) is a selective sodium glucose cotransporter 2 inhibitor in clinical development for the treatment of patients with type 2 diabetes mellitus (T2DM).


      The primary objective was to evaluate the safety profile and tolerability of ipragliflozin as a glucose-lowering agent in combination with stable metformin therapy in patients with T2DM. A secondary objective was to evaluate the effect of ipragliflozin on the pharmacokinetic (PK) properties of metformin.


      Thirty-six patients with T2DM stable on metformin therapy (850, 1000, or 1500 mg bid) were randomized in a double-blind manner to receive ipragliflozin (300 mg qd; n = 18) or matching placebo (n = 18) for 14 days. Safety profiles, including monitoring of hypoglycemic events, treatment-emergent adverse events (TEAEs), laboratory measurements, and vital signs were assessed throughout the study. The PK properties of metformin and ipragliflozin were determined in plasma. The geometric mean ratio and its 90% CI for the maximum plasma concentration and AUC0–10 were calculated for metformin + ipragliflozin (day 14) versus metformin alone (day −1). Pharmacodynamic properties were assessed by measurement of urinary glucose excretion over 24 hours (UGE0–24).


      All the TEAEs, except 1, were mild. Fifteen TEAEs were observed in the ipragliflozin group (7 of 18 patients [38.9%]), and 19 TEAEs were observed in the placebo group in (8 of 18 patients [44.4%]). Treatment-related TEAEs were reported by 3 of 18 patients (16.7%) receiving metformin + ipragliflozin and by 5 of 18 patients (27.8%) receiving metformin + placebo. No hypoglycemic events (blood glucose level <54 mg/L [to convert to millimoles per liter, multiply by 0.0555]) were observed. The geometric mean ratios for Cmax and AUC0–10 of metformin + ipragliflozin versus metformin alone were 1.11 (90% CI, 1.03–1.19) and 1.18 (90% CI, 1.08–1.28), respectively. After ipragliflozin treatment, UGE0–24 on day 14 (74.9 g) was significantly higher than that in the placebo group (3.6 g) and at baseline (3.3 g).


      Combination treatment for 14 days with ipragliflozin and metformin was well tolerated in patients withT2DM without hypoglycemia. The addition of ipragliflozin (300 mg qd) to metformin therapy did not result in a clinically relevant change in the PK properties of metformin. identifier: NCT01302145.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Wright E.M.
        Renal Na+-glucose cotransporters.
        Am J Physiol Renal Physiol. 2001; 280: F10-F18
        • Neumiller J.J.
        • White Jr, J.R.
        • Campbell R.K.
        Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.
        Drugs. 2010; 70: 377-385
        • Kanai Y.
        • Lee W.S.
        • You G.
        • et al.
        The human kidney low affinity Na+/glucose cotransporter SGLT2: delineation of the major renal reabsorptive mechanism for D-glucose.
        J Clin Invest. 1994; 93: 397-404
        • Jabbour S.A.
        • Goldstein B.J.
        Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes.
        Int J Clin Pract. 2008; 62: 1279-1284
        • Veltkamp S.
        • Opdam F.
        Treatment of patients with type 2 diabetes mellitus: new therapies on the horizon [in Dutch].
        PW Wetenschappelijk Platform. 2011; 5: a1135
        • Veltkamp S.A.
        • Kadokura T.
        • Krauwinkel W.J.J.
        • Smulders R.A.
        Effect of ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.
        Clin Drug Investig. 2011; 31: 839-851
        • Tahara A.
        • Kurosaki E.
        • Yokono M.
        • et al.
        Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
        Naunyn Schmiedebergs Arch Pharmacol. 2012; 385: 423-436
        • Kadokura T.
        • Saito M.
        • Utsuno A.
        • et al.
        Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects.
        Diabetol Int. 2011; 2: 172-182
        • Schwartz S.L.
        • Akinlade B.
        • Klasen S.
        • et al.
        Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.
        Diabetes Technol Ther. 2011; 13: 1219-1227
        • Kashiwagi A.
        • Utsuno A.
        • Kazuta K.
        • et al.
        ASP1941, a novel, selective SGLT2 inhibitor, was effective and safe in Japanese healthy volunteers and patients with type 2 diabetes mellitus.
        Abstract presented at: 70th American Diabetes Association Conference; Orlando, Fla. 2010;
        • Tahrani A.A.
        • Bailey C.J.
        • Del Prato S.T.
        • et al.
        Management of type 2 diabetes: new and future developments in treatment.
        Lancet. 2011; 378: 182-197
        • Bailey C.J.
        The challenge of managing coexistent type 2 diabetes and obesity.
        BMJ. 2011; 342: d1996
        • McIntosh B.
        • Cameron C.
        • Singh S.
        • et al.
        Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.
        Open Med. 2011; 5: e35-e48
        • Nathan D.M.
        • Buse J.B.
        • Davidson M.B.
        • et al.
        Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.
        Diabetes Care. 2009; 32: 193-203
        • Turner R.C.
        • Cull C.A.
        • Frighi V.
        • Holman R.R.
        • UK Prospective Diabetes Study (UKPDS) Group
        Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49).
        JAMA. 1999; 281: 2005-2012
        • Sirtori C.R.
        • Pasik C.
        Re-evaluation of a biguanide, metformin: mechanism of action and tolerability.
        Pharmacol Res. 1994; 30: 187-228
        • American Diabetes Association
        Standards of Medical Care in Diabetes—2012.
        Diabetes Care. 2012; 35: S11-S63
        • Davidson J.
        • Howlett H.
        New prolonged-release metformin improves gastrointestinal tolerability.
        Brit J Diabetes Vasc Dis. 2004; 4: 273-277
        • Smulders R.A.
        • Zhang W.
        • Veltkamp S.A.
        • et al.
        No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.
        Diabetes Obes Metab. 2012 May 15; ([Epub ahead of print])
        • Ushigome F.
        Astellas Validation Report.
        Internal report 1941-ME-0029: inhibitory effect of ASP1941 on human OCT1- and OCT2-mediated transport of metformin using HEK293 cells expressing OCTs. 2011; (unpublished data)
        • Veltkamp S.A.
        • van Dijk J.
        • Krauwinkel W.J.J.
        • Smulders R.A.
        The effect of renal impairment on the pharmacokinetics and urinary glucose excretion of the SGLT2 inhibitor ASP1941 in type 2 diabetes mellitus patients.
        Abstract presented at: 71st Scientific Sessions of the American Diabetes Association. 2011; (San Diego, Ca)
        • Kadokura T.
        • Ishikawa H.
        • Nakajo I.
        • et al.
        The effect of renal impairment on the pharmacokinetics and urinary glucose excretion of the SGLT2 inhibitor ipragliflozin (ASP1941) in Japanese T2DM patients.
        Abstract presented at: 47th annual meeting of the European Association for the Study of Diabetes; September 12–16. 2011; (Lisbon, Portugal)
        • Good Clinical Practice
        (Accessed July 9, 2012)
      1. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.
        JAMA. 2000; 284: 3043-3045
        • BASi Validation Report
        Internal Report 1000-081228 “Validation of an Analytical Method for the Determination of ASP1941 in Lithium Heparinized Human Plasma using LC-MS/MS.”. 2009; (unpublished data)
        • SGS Validation Report
        Internal Report CP055376 “Validation of an LC MS/MS Method for the Determination of Metformin in Human Plasma.”. 2009; (unpublished data).
        • SGS Validation Report
        Internal Report CP085310 “Complementary Validation of an Analytical Method for the Determination of Metformin in Human Plasma by LC-MS/MS.”. 2009; (unpublished data).
      2. Rowland M. Tozer T.N. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. 4th ed. Lippincott William & Wilkins, Philadelphia, Pa2009
      3. Gabrielsson J. Weiner D. Pharmacokinetic–Pharmacodynamic Data Analysis: Concepts and Applications. 2nd ed. Apotekarsocieteten, Stockholm, Sweden1997: 770
        • Wang D.-S.
        • Jonker J.W.
        • Kato Y.
        • et al.
        Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin.
        J Pharmacol Exp Ther. 2002; 302: 510-515
        • Sogame Y.
        • Kitamura A.
        • Yabuki M.
        • Komuro S.
        A comparison of uptake of metformin and phenformin mediated by hOCT1 in human hepatocytes.
        Biopharm Drug Dispos. 2009; 30: 476-484
        • Wilding J.P.
        • Ferrannini E.
        • Fonseca V.
        • et al.
        Efficacy and safety of ipragliflozin in type 2 diabetes patients inadequately controlled on metformin: a dose-finding study.
        in: Abstract presented at: World Diabetes Congress 2011, December 4-8, 2011; Dubai, United Arab Emirates2011